Literature DB >> 8437112

Pulmonary antiallergic and bronchodilator effects of isozyme-selective phosphodiesterase inhibitors in guinea pigs.

R E Howell1, B D Sickels, S L Woeppel.   

Abstract

The effectiveness of theophylline (aminophylline) in treating asthma may result in part from nonselective inhibition of multiple isozymes of cyclic nucleotide phosphodiesterase (PDE). The roles for inhibition of different PDE isozymes in the pulmonary antiallergic and bronchodilator effects of theophylline were investigated in anesthetized and ventilated guinea pigs by using the PDE-III-selective inhibitor Cl-930, the PDE-IV-selective inhibitor rolipram and the PDE-V-selective inhibitor zaprinast. Aminophylline, Cl-930 and rolipram inhibited aerosol ovalbumin-induced full [leukotriene (LT) + histamine] and LT-dependent bronchoconstriction, but zaprinast was inactive. At doses producing an equieffective inhibition of antigen-induced full bronchoconstriction, aminophylline and Cl-930 produced a similar inhibition of aerosol histamine-induced bronchoconstriction, whereas rolipram produced much less inhibition of histamine-induced bronchoconstriction. At doses producing an equieffective inhibition of antigen-induced LT-dependent bronchoconstriction, aminophylline and Cl-930 produced a similar inhibition of i.v. LTD4-induced bronchoconstriction, whereas rolipram did not inhibit LTD4-induced bronchoconstriction. Acute airway hyperreactivity was evidenced by significant leftward shifts in dose-response curves to i.v. methacholine-induced bronchoconstriction 24 hr after aerosol ovalbumin challenge. Aminophylline and rolipram prevented airway hyperreactivity without causing residual bronchodilation 24 hr after antigen challenge. In contrast, Cl-930 failed to inhibit airway hyperreactivity, but produced substantial residual bronchodilation. The results indicate that PDE-IV inhibition produces pulmonary antiallergic effects in vivo, including the apparent inhibition of LT release, which may contribute to the antiasthmatic actions of theophylline. The results also support previous suggestions that PDE-III inhibition contributes to the bronchodilator effect of theophylline.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8437112

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

Review 1.  Phosphodiesterase 4 inhibitors and the treatment of asthma: where are we now and where do we go from here?

Authors:  M A Giembycz
Journal:  Drugs       Date:  2000-02       Impact factor: 9.546

2.  Pulmonary antiallergic and antiinflammatory effects of a novel, orally-active phosphodiesterase IV inhibitor (WAY-127093B) in guinea pigs and rats.

Authors:  R E Howell; S L Woeppel; D E Howell; E B Rubin; L P Jenkins; J M Golankiewicz; L J Lombardo; R J Heaslip
Journal:  Inflamm Res       Date:  1995-08       Impact factor: 4.575

3.  Effects of selective phosphodiesterase inhibitors on platelet-activating factor- and antigen-induced airway hyperreactivity, eosinophil accumulation, and microvascular leakage in guinea pigs.

Authors:  J L Ortiz; J M Vallés; M Martí-Cabrera; J Cortijo; E J Morcillo
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-01       Impact factor: 3.000

4.  Effects of agents which elevate cyclic AMP on guinea-pig eosinophil homotypic aggregation.

Authors:  M M Teixeira; A G Rossi; M A Giembycz; P G Hellewell
Journal:  Br J Pharmacol       Date:  1996-08       Impact factor: 8.739

5.  Pulmonary effects of type V cyclic GMP specific phosphodiesterase inhibition in the anaesthetized guinea-pig.

Authors:  N C Turner; J S Dolan; D Grimsditch; J Lamb; A Worby; K J Murray; W J Coates; B H Warrington
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

6.  Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig.

Authors:  M M Teixeira; A G Rossi; T J Williams; P G Hellewell
Journal:  Br J Pharmacol       Date:  1994-05       Impact factor: 8.739

7.  Effect of the glucocorticosteroid budesonide and a novel phosphodiesterase type 4 inhibitor CDP840 on antigen-induced airway responses in neonatally immunised rabbits.

Authors:  N Gozzard; A el-Hashim; C M Herd; S M Blake; M Holbrook; B Hughes; G A Higgs; C P Page
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

8.  The inhibition of antigen-induced eosinophilia and bronchoconstriction by CDP840, a novel stereo-selective inhibitor of phosphodiesterase type 4.

Authors:  B Hughes; D Howat; H Lisle; M Holbrook; T James; N Gozzard; K Blease; P Hughes; R Kingaby; G Warrellow; R Alexander; J Head; E Boyd; M Eaton; M Perry; M Wales; B Smith; R Owens; C Catterall; S Lumb; A Russell; R Allen; M Merriman; D Bloxham; G Higgs
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  Inhibition of allergen-induced lung eosinophilia by type-III and combined type III- and IV-selective phosphodiesterase inhibitors in brown-Norway rats.

Authors:  W Elwood; J Sun; P J Barnes; M A Giembycz; K F Chung
Journal:  Inflamm Res       Date:  1995-02       Impact factor: 4.575

10.  Effects of theophylline and rolipram on antigen-induced airway responses in neonatally immunized rabbits.

Authors:  N Gozzard; C M Herd; S M Blake; M Holbrook; B Hughes; G A Higgs; C P Page
Journal:  Br J Pharmacol       Date:  1996-04       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.